EP2268296A1 - Compositions et procédé permettant de diagnostiquer, de prévenir et de traiter la maladie d'alzheimer - Google Patents
Compositions et procédé permettant de diagnostiquer, de prévenir et de traiter la maladie d'alzheimerInfo
- Publication number
- EP2268296A1 EP2268296A1 EP08848333A EP08848333A EP2268296A1 EP 2268296 A1 EP2268296 A1 EP 2268296A1 EP 08848333 A EP08848333 A EP 08848333A EP 08848333 A EP08848333 A EP 08848333A EP 2268296 A1 EP2268296 A1 EP 2268296A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fcγriib
- interaction
- screening
- inhibitor
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 101
- 238000003745 diagnosis Methods 0.000 title abstract description 6
- 239000000203 mixture Substances 0.000 title description 12
- 230000002265 prevention Effects 0.000 title description 5
- 201000010099 disease Diseases 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 3
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims abstract description 331
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims abstract description 326
- 239000003112 inhibitor Substances 0.000 claims abstract description 87
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 76
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 73
- 230000014509 gene expression Effects 0.000 claims abstract description 65
- 238000012216 screening Methods 0.000 claims abstract description 53
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 46
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 45
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 41
- 230000003834 intracellular effect Effects 0.000 claims abstract description 41
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 38
- 230000000694 effects Effects 0.000 claims abstract description 31
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 230000019491 signal transduction Effects 0.000 claims abstract description 9
- 230000027455 binding Effects 0.000 claims description 97
- 210000004027 cell Anatomy 0.000 claims description 76
- 230000003993 interaction Effects 0.000 claims description 71
- 150000001875 compounds Chemical class 0.000 claims description 60
- 235000018102 proteins Nutrition 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 23
- 102000005962 receptors Human genes 0.000 claims description 21
- 108020003175 receptors Proteins 0.000 claims description 21
- 150000001413 amino acids Chemical group 0.000 claims description 19
- 210000004556 brain Anatomy 0.000 claims description 19
- 102000037865 fusion proteins Human genes 0.000 claims description 17
- 108020001507 fusion proteins Proteins 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 230000005945 translocation Effects 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 13
- 238000001262 western blot Methods 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 12
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 11
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 10
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 9
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 9
- 210000004958 brain cell Anatomy 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 8
- 238000011161 development Methods 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 101150013553 CD40 gene Proteins 0.000 claims description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 7
- 230000004715 cellular signal transduction Effects 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 210000004897 n-terminal region Anatomy 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- 101150058160 Lyn gene Proteins 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 6
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 claims description 5
- 102000004008 5'-Nucleotidase Human genes 0.000 claims description 5
- 108010073807 IgG Receptors Proteins 0.000 claims description 5
- 102000009490 IgG Receptors Human genes 0.000 claims description 5
- 101710144867 Inositol monophosphatase Proteins 0.000 claims description 5
- 101710180095 Inositol-1-monophosphatase Proteins 0.000 claims description 5
- 101710081113 Inositol-1-monophosphatase SuhB Proteins 0.000 claims description 5
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 claims description 5
- 101710173384 Nus factor SuhB Proteins 0.000 claims description 5
- 101710113809 Putative Nus factor SuhB Proteins 0.000 claims description 5
- ACPOUJIDANTYHO-UHFFFAOYSA-N anthra[1,9-cd]pyrazol-6(2H)-one Chemical compound C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 102000001253 Protein Kinase Human genes 0.000 claims description 4
- JKOCAAWWDVHWKB-UHFFFAOYSA-N [1-(4-hydroxyphenoxy)-1-phosphonoethyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(C)OC1=CC=C(O)C=C1 JKOCAAWWDVHWKB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 4
- 108060006633 protein kinase Proteins 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- DDSBPUYZPWNNGH-UHFFFAOYSA-N 6-n-[(4-nitrophenyl)methyl]-2-n-[[3-(trifluoromethyl)phenyl]methyl]-7h-purine-2,6-diamine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CNC1=NC(NCC=2C=C(C=CC=2)C(F)(F)F)=NC2=C1NC=N2 DDSBPUYZPWNNGH-UHFFFAOYSA-N 0.000 claims description 3
- 101000852579 Caenorhabditis elegans Inositol-trisphosphate 3-kinase homolog Proteins 0.000 claims description 3
- 108091007911 GSKs Proteins 0.000 claims description 3
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 238000003018 immunoassay Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000026731 phosphorylation Effects 0.000 claims description 3
- 238000006366 phosphorylation reaction Methods 0.000 claims description 3
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 238000001917 fluorescence detection Methods 0.000 claims description 2
- 230000037041 intracellular level Effects 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 238000003158 yeast two-hybrid assay Methods 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims 3
- 230000001054 cortical effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 33
- 230000007135 neurotoxicity Effects 0.000 abstract description 15
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 208000000044 Amnesia Diseases 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 231100000863 loss of memory Toxicity 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000010807 negative regulation of binding Effects 0.000 abstract 1
- 230000009223 neuronal apoptosis Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 description 37
- 230000011664 signaling Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 230000000692 anti-sense effect Effects 0.000 description 13
- 230000030833 cell death Effects 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 230000016273 neuron death Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 206010029350 Neurotoxicity Diseases 0.000 description 9
- 206010044221 Toxic encephalopathy Diseases 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 231100000228 neurotoxicity Toxicity 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108091027967 Small hairpin RNA Proteins 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000004055 small Interfering RNA Substances 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000000018 DNA microarray Methods 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- 230000007154 intracellular accumulation Effects 0.000 description 5
- 230000008897 memory decline Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 231100000189 neurotoxic Toxicity 0.000 description 5
- 230000002887 neurotoxic effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000019581 neuron apoptotic process Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 230000007082 Aβ accumulation Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000003618 cortical neuron Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000031146 intracellular signal transduction Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 102000007590 Calpain Human genes 0.000 description 2
- 108010032088 Calpain Proteins 0.000 description 2
- PGGUOGKHUUUWAF-ROUUACIJSA-N Calpeptin Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 PGGUOGKHUUUWAF-ROUUACIJSA-N 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 2
- 102000000254 Kv Channel-Interacting Proteins Human genes 0.000 description 2
- 108010041081 Kv Channel-Interacting Proteins Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 description 2
- 241000644027 Perideridia lemmonii Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 2
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 108010082989 calpeptin Proteins 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 230000007463 intraneuronal Aβ accumulation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000011302 passive avoidance test Methods 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 239000002924 silencing RNA Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 2
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000613565 Homo sapiens PRKC apoptosis WT1 regulator protein Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 238000002990 Monte Carlo minimization method Methods 0.000 description 1
- 101100066431 Mus musculus Fcgr2 gene Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 108010080178 N-benzyloxycarbonyl-valyl-leucyl-leucinal Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710162991 PRKC apoptosis WT1 regulator protein Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101000708422 Podarcis siculus Tissue- and phase-specific nuclear protein Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000005405 multipole Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108010061506 tau-protein kinase Proteins 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- JOLJIIDDOBNFHW-UHFFFAOYSA-N xanomeline Chemical compound CCCCCCOC1=NSN=C1C1=CCCN(C)C1 JOLJIIDDOBNFHW-UHFFFAOYSA-N 0.000 description 1
- 229950006755 xanomeline Drugs 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Definitions
- the present invention relates to methods of diagnosing, preventing and treating Alzheimer' s disease based on the use of an inhibitor for the binding of amyloid- ⁇ to Fc ⁇ RIIb, and a method of screening the inhibitor. More particularly, the present invention relates to methods of diagnosing, preventing and treating Alzheimer' s disease using an inhibitor of the binding between amyloid- ⁇ and Fc ⁇ RIIb, which is selected from the group consisting of an Fc ⁇ RIIb protein or a variant thereof, an Fc ⁇ RIIb extracellular domain, an anti-Fc ⁇ RIIb antibody, a specific peptide and an Fc ⁇ RIIb-specific siRNA, and a method of screening the inhibitor.
- an inhibitor of the binding between amyloid- ⁇ and Fc ⁇ RIIb which is selected from the group consisting of an Fc ⁇ RIIb protein or a variant thereof, an Fc ⁇ RIIb extracellular domain, an anti-Fc ⁇ RIIb antibody, a specific peptide and an Fc ⁇ RIIb-specific siRNA,
- AD Alzheimer's disease
- familial AD which has genetic links and runs in families
- sporadic AD which develops in many people for no obvious reason.
- AD patients typically have multiple cognitive deficiencies, which are manifested by memory impairment and psychological symptoms such as psychosomatic abnormalities, including increased anxiety and hypersensitivity.
- Two pathological hallmarks are seen in the brains of patients who die of AD: senile plaques and neurofibrillary tangles.
- Senile plaques are extracellular accumulations of proteins and dead cells, and are primarily composed of amyloid- ⁇ (A ⁇ ) peptides (Hardy, J. et al., Nat Neurosci. 1:355-358, 1998) .
- a ⁇ amyloid- ⁇
- a ⁇ is produced from amyloid precursor protein (APP) through proteolytic cleavage.
- APP is cleaved by ⁇ - secretase (BACE) and ⁇ -secretase, yielding A ⁇
- BACE ⁇ - secretase
- a ⁇ A ⁇ is produced from amyloid precursor protein (APP) through proteolytic cleavage.
- APP is cleaved by ⁇ - secretase (BACE) and ⁇ -secretase, yielding A ⁇ (Craven, R., Nat Rev. Neurosci. 2: 533, 2001; David, H. S. et al., Nat Rev. Neurosci. 2: 595-598, 2001; Yankner, B. A., Neuron 16: 921-932, 1996; Selkoe, D. J., Nature 399: A23-A31, 1999) .
- BACE ⁇ - secretase
- AD Alzheimer's disease
- Current medications for AD include nicotinic receptor agonists, such as ABT-418; muscarinic receptor agonists, such as Xanomeline and YM-976; acetylcholine precursors, such as lecithin and acetyl-L- carnitine; metal chelators, such as desferrioxamine and clioquinol; beta-sheet breakers, such as iA ⁇ 5 and iA ⁇ ll; antioxidants, such as vitamin E, Ginkgo biloba, melatonin and idebenone; sAPP releasing agents, such as nicotine, acetylcholine and carbachol; ⁇ -secretase or ⁇ -secretase inhibitors, such as OM99-1, OM99-2, OM99-3 and Z-
- Pro- apoptotic genes such as prostate apoptosis response-4 (Par-4), tau protein kinase 1 (GSK-3 ⁇ ) , Calsenilin/DREAM/KChIP3, and cell death-promoting gene 5 (DP5), are shown to be overexpressed or their activities are increased in neuronal cells cultured in the presence of
- a ⁇ or neuronal cells from AD patients The blocking of the functions of the proteins reduces A ⁇ -induced neuronal death
- Fc ⁇ RIIb Fc ⁇ receptor lib
- Fc ⁇ RIIb receptor has recently been known to play a regulatory role in arthritis (Nakamura, A. et al., Biomed. Pharmacother. 58: 292-298, 2004) .
- the involvement of Fc ⁇ RIIb in dementia and its potential as a therapeutic target for dementia have not been known.
- Fc ⁇ RIIb serves as a receptor for A ⁇ as well as playing an immunoregulatory role.
- Fc ⁇ RIIb acts as a protein mediating A ⁇ neurotoxicity and serves as a receptor in an A ⁇ -initiated toxic signaling pathway, through which Fc ⁇ RIIb binds A ⁇ as the first event of the toxic signaling in neuronal cells and transduces the cell death signal into the cells.
- Fc ⁇ RIIb enhances A ⁇ deposition, associated with memory impairment in AD, within neuronal cells.
- an Fc ⁇ RIIb protein or a variant thereof, an Fc ⁇ RIIb extracellular domain, an anti-Fc ⁇ RIIb antibody, an Fc ⁇ R ⁇ Ib-specific peptide and an Fc ⁇ RIIb-specific siRNA suppress neuronal cell death and prevent memory loss in subjects, thereby leading to the present invention.
- the present invention provides a method of preventing and treating Alzheimer's disease, by inhibiting binding of A ⁇ to Fc ⁇ RIIb.
- the present invention also provides an inhibitor for the binding of A ⁇ to Fc ⁇ RIIb.
- the inhibitor includes an
- Fc ⁇ RIIb protein or a variant thereof an Fc ⁇ RIIb extracellular domain, an anti-Fc ⁇ RIIb antibody, an Fc ⁇ RIIb- specific peptide, and an Fc ⁇ RIIb-specific siRNA.
- the present invention further provides a method of screening an agent inhibiting the interaction between A ⁇ and Fc ⁇ RIIb.
- the screening method includes screening an agent inhibiting the activity of Fc ⁇ RIIb, an agent suppressing the expression of Fc ⁇ RIIb, an agent inhibiting the transduction of the toxic signal of A ⁇ into neuronal cells through Fc ⁇ RIIb, and an agent inhibiting the interaction between A ⁇ and Fc ⁇ RIIb.
- the ordinary skilled person may use computer software-based methods to identify the agent inhibiting the interaction between A ⁇ and Fc ⁇ RIIb.
- the present invention still further provides a method of diagnosing Alzheimer' s disease comprising determining the expression level of Fc ⁇ RIIb.
- the present invention still further provides a kit for diagnosing Alzheimer' s disease comprising reagents used for determining the expression level of Fc ⁇ RIIb.
- the present invention still further provides a method of preventing and treating Alzheimer' s disease based on the use of the method of inhibiting the interaction between A ⁇ and Fc ⁇ RIIb.
- a "peptide” means a molecule comprising two or more amino acids linked each other via peptide bond.
- the peptide may be chemically synthesized or prepared by common genetic engineering technologies.
- RNA or "small interfering RNA” means an RNA molecule binding to a particular tagert mRNA and knock-out the mRNA, and may be a double stranded RNA molecule having a homologous seguence selected from the target mRNA and consisting of 17 to 25 consecutive nucleotide or may be a short hairpin RNA (hereinafter referred as "shRNA”) comprising sequentially the homologous sequence, a loop and a complementary sequence of the homologous sequence thereby forming a stem-loop structure.
- shRNA short hairpin RNA
- the si RNA may be prepared by chemical synthesis of RNA oligonucleotides, in vitro transcription, cleavage of long dsRNA transcribed in vitro using RNase III or Dicer, expression through celluar transduction of plasmid or viral vector expressing siRNA or cellular transduction of PCR-derived siRNA expression cassette .
- a “variant” or “mutant” means a peptide having conserved amino acids for keeping the function thereof and whose one or more non-essential amino acids are substituted with different amino acids but reserving the original function .
- an “inhibitor of interaction” means a substance inhibiting the interaction between proteins and includes compositions comprising a protein or a peptide inhibiting interaction between proteins or an antibody against the protein or the peptide or expression inhibitors.
- an “expression inhibitor” means a material inhibiting transcription or translation of a particular gene. It includes compositions comprising molecules commonly used for inhibition of expression of the gene such as siRNA, shRNA, microRNA (hereinafter referred as "miRNA”) and antisense oligonucleotide.
- control group means an experimental group treated with only buffer solution used for solving a tested compound or a compound known to have no effect on a target.
- Fc ⁇ RIIb chimeric protein means a chimeric (or fusion) protein of Fc ⁇ RIIb with an effector protein (a protein activating the expression, color development or color change of a specific protein or cellular signal transduction upon the interaction between Fc ⁇ RIIb and A ⁇ ) .
- Fo ⁇ receptor lib extracellular domain means a portion of Fc ⁇ RIIb which is exposed to extracellular space.
- Fo ⁇ receptor lib extracellular domain When recombinantly produced Fo ⁇ receptor lib extracellular domain is administrated to a subject, it can induce competitive inhibition with intrinsic Fey receptor libs.
- an “antibody” means an immunoglobulin such as IgG, IgM and IgA or active fragment thereof such as Fab, F(ab')2 and ScFv, which binds to a target antigen specifically.
- the antibody may be a polyclonal antibody prepared by immunizing a mammal such as a rabbit, a mouse, a rat or a goat through injecting a purified antigen along with an adjuvant; collecting blood from the mammal; and purifying antibodies using affinity column using protein A or G.
- the antibody may be a monoclonal antibody prepared by obtaining spleen cells from the immunized mammal; producing hybridoma with myeloma cells; and culturing the hybridoma under a selection medium.
- the monoclonal antibody may be produced as a humanized antibody prepared by analyzing a gene encoding said monoclonal antibody; determining complementary determining region (hereinafter referred as "CDR") ; reserving the CDR and replacing framework regions (hereinafter referred as "FRs”) with human FRs. More preferably, a human antibody may be used by screening human antibody cDNA library using phage display technologies, etc. DETAILED DESCRIPTION OF THE INVENTION
- the present invention provides a method of preventing and treating AD by inhibiting the binding of A ⁇ to Fc ⁇ RIIb.
- the present inventors identified a receptor for A ⁇ , which is the major pathological cause of AD, on neuronal cells, and, based on this finding, developed a method of preventing and treating AD by inhibiting the association between A ⁇ and Fc ⁇ RIIb.
- the expression of Fc ⁇ RIIb was found to increase in neuronal cells exposed to A ⁇ (FIG. 1) .
- a Fc ⁇ RIIb wild type and a Fc ⁇ RIIb variant were prepared and administered to neuronal cells along with A ⁇ .
- cells treated with the Fc ⁇ RIIb variant were found to exhibit reduced cell death rates (FIG. 2) .
- the present inventors prepared siRNAs to suppress the transcription of Fc ⁇ RIIb and RAGE, which is known to be a cell surface receptor for A ⁇ (FIG. 3a) .
- the transcriptional suppression of RAGE expression did not result in any increase in cell survival, whereas all cells survived when the transcription of Fc ⁇ RIIb was suppressed (FIG. 3b) .
- Fc ⁇ RIIb rather than RAGE is the direct cell surface protein for A ⁇ signaling.
- Fc ⁇ RIIb extracellular domain was prepared, and neuronal cells exposed to A ⁇ were treated with this extracellular domain and examined for cell survival rates.
- the increased expression of Fc ⁇ RIIb due to exposure to A ⁇ was suppressed (FIG. 4a), and the relative cell viability was increased to that of cells not exposed to A ⁇ (FIG. 4b) .
- Fc ⁇ RIIb-mediated neuronal transduction of A ⁇ signaling was inhibited.
- the in vivo distribution of A ⁇ and FcyRIIb was examined.
- Oligomeric A ⁇ and Fc ⁇ RIIb were found to be co- localized in the brain tissue of Tg2576 mouse which is an animal model for AD, indicating that both of them are present in the same region (FIG. 5a) . Also, A ⁇ was expressed together with Fc ⁇ RIIb in brain specimens from AD patients, confirming that both of them are present in the same cells (FIG. 5b) . The transcriptional suppression of RAGE expression did not result in a decrease in the intracellular accumulation of A ⁇ , whereas the transcriptional suppression of Fc ⁇ RIIb expression markedly reduced intracellular A ⁇ accumulation (FIG. 6) . These results indicate that Fc ⁇ RIIb is involved in the intracellular accumulation of A ⁇ as well as in intracellular signal transduction of A ⁇ . Based on the above results, the binding between A ⁇ and Fc ⁇ RIIb was examined in vitro. The in vitro experiment revealed that A ⁇ binds to Fc ⁇ RIIb (FIGs. 7 and 8) .
- a ⁇ bound to Fc ⁇ RIIb identified for the first time the structure of A ⁇ bound to Fc ⁇ RIIb using a computer program.
- researchers have made many efforts to determine the structure of A ⁇ , but failed to crystallize A ⁇ .
- a ⁇ is difficult to crystallize because it is present as amorphous aggregates, called amyloid plaques, in AD patients.
- amyloid plaques amorphous aggregates
- AD patients amorphous aggregates
- soluble oligomers of A ⁇ play a major role in neuronal toxicity.
- the three-dimensional structure of A ⁇ oligomers was determined by simulating the stable oligomerization of A ⁇ monomers using in silico methods (Urbane, B. et al., Proc. Natl.
- the present inventors predicted the Fc ⁇ RIIb-bound structure of A ⁇ using the known three-dimensional structures of A ⁇ and Fc ⁇ RIIb. This predicted structure showed that the structures of A ⁇ and Fc ⁇ RIIb precisely fit together (FIG. 9) .
- a ⁇ binds to an extracellular domain of Fc ⁇ RIIb.
- a ⁇ is present in oligomeric forms, in which hydrophilic N- terminal regions are flexible and C-terminal regions aggregate to form an oligomer.
- the present inventors found that extended N-terminal regions bind Fc ⁇ RIIb to exert cytotoxicity using Insight II/Affinity program (Acelrys Co. , USA) .
- Trp87 and TrpllO of Fc ⁇ RIIIb interacts with a proline residue at 329 (Pro329) of IgG (Sondermann P. et al.,
- the present inventors conducted an in silico simulation based on the above results. This simulation showed that a phenylalanine residue at position 4 of A ⁇ makes a strong hydrophobic interaction with two tryptophan residues, Trp92 and Trpll5, of Fc ⁇ RIIb, an aspartate residue at position 7 of A ⁇ makes a strong hydrophilic interaction with two lysine residues, Lysll ⁇ and Lysll ⁇ , of Fc ⁇ RIIb, a glutamine residue at position 3 of A ⁇ makes a relatively weak interaction with Tyrl65 of Fc ⁇ RIIb, and Arg5 and His6 residues of A ⁇ rarely interact with residues of Fc ⁇ RIIb.
- the present inventors prepared peptides capable of inhibiting the binding between A ⁇ and Fc ⁇ RIIb.
- the peptides were found to effectively inhibit the binding between A ⁇ and Fc ⁇ RIIb (FIGs. 10 and 11) .
- mice The peptides were injected into the brain of mice, and the memory ability of mice was assessed. As a result, memory impairment, as seen in AD cases, was remarkably restored (FIG. 12) . Also, the mice treated with the peptide inhibitors displayed no accumulation of the full length A ⁇ i- 42 peptide in the brain (FIG. 13) .
- the present invention provides interaction inhibitors inhibiting the interaction between A ⁇ and Fc ⁇ RIIb.
- the interaction inhibitors may be selected from the group consisting of an Fc ⁇ RIIb protein or a variant thereof, an Fc ⁇ RIIb extracellular domain, an anti-Fc ⁇ RIIb antibody, a peptide inhibiting the binding between A ⁇ and Fc ⁇ RIIb, and an Fc ⁇ RIIb expression inhibitor including an Fc ⁇ RIIb-specific siRNA or an Fc ⁇ RIIb-specific antisense nucleotide.
- An Fc ⁇ RIIb protein or a variant thereof competes with endogenous Fc ⁇ RIIb in neuronal cells for A ⁇ binding to inhibit the binding of A ⁇ to endogenous Fc ⁇ RIIb.
- a cell death signal of A ⁇ is not transduced into neuronal cells, thus preventing cell death.
- the Fc ⁇ RIIb protein has the nucleotide seguence of SEQ ID No. 35 and the amino acid sequence of SEQ ID No. 36, and variants thereof are also available.
- an Fc ⁇ RIIb variant is prepared by replacing an isoleucine residue at 232 of human Fc ⁇ RIIb with threonine, and has the amino acid sequence of SEQ ID No. 37.
- the variant is not specifically limited thereto, and any variant in which other residues of Fc ⁇ RIIb are mutated and which is able to modulate the signal transduction mediated by Fc ⁇ RIIb is available.
- a ⁇ -induced neuronal cell death decreased ( FIG . 2 ) .
- Fc ⁇ RIIb is composed of an extracellular domain and an intracellular domain, and the extracellular domain binds to A ⁇ .
- the extracellular domain also competes with endogenous Fc ⁇ RIIb in neuronal cells for A ⁇ binding to thus inhibit the binding of A ⁇ to endogenous Fc ⁇ RIIb, thereby inhibiting neuronal cell death.
- the Fc ⁇ RIIb extracellular domain may be any one derived from humans, mice, rats, or the like. Preferred is a human-derived extracellular domain of Fc ⁇ RIIb.
- the Fc ⁇ RIIb extracellular domain may be produced using a method known to those skilled in the art, for example, through cloning into E.
- the FcyRIIb extracellular domain is purified using a method described in Sondermann P. et al. [EMBO J., 18(5) : 1095-1103, 1999) .
- the Fc ⁇ RIIb extracellular domain was found to increase the relative viability of neuronal cells exposed to A ⁇ to the same level as cells not exposed to A ⁇ (FIG. 4) .
- An anti-Fc ⁇ RIIb antibody prepared using the entire region or extracellular domain of Fc ⁇ RIIb as an antigen, competes with A ⁇ for Fc ⁇ RIIb binding and thus inhibits the binding of A ⁇ to Fc ⁇ RIIb in neuronal cells.
- the peptide is designed based on an amino acid sequence predicted as a binding site of A ⁇ to Fc ⁇ RIIb or vice versa (see FIG. 9), but is not limited thereto.
- the peptide is a peptide or a mutant thereof, which consists of one to nine amino acids comprising phenylalanine at position 4 of SEQ ID No. 24, corresponding to the N- terminal region of A ⁇ .
- the peptide is an amino acid, a peptide or a mutant thereof, which consists of one to nine amino acids, comprising tryptophan at position 5 of SEQ ID No.
- peptides were designed to have sequences represented by SEQ ID Nos. 24 to 33 (peptides #1 to #10, respectively), but are not limited thereto.
- SEQ ID Nos. 24 to 33 peptides #1 to #10, respectively
- specific peptides #1, #4 and #9 effectively inhibited the binding between Fc ⁇ RIIb-CD40 and A ⁇ (FIG. 10) .
- neuronal cells were treated with the peptides and A ⁇ , cells exhibited increased survival (FIG. 11) .
- peptides were injected along with A ⁇ into the brains of mice, and mice were assessed for memory ability. Peptides #1 and #9 were found to restore A ⁇ -induced memory decline (FIG. 12) . The immunohistochemical analysis of the brain of experimental animals showed that peptide #1 completely inhibited intracellular accumulation of A ⁇ in neuronal cells (FIG. 13) .
- Fc ⁇ RIIb expression inhibitor refers collectively to substances that specifically inhibit the transcriptional or translational expression of Fc ⁇ RIIb, and may include siRNAs, antisense nucleotides and compounds.
- Fc ⁇ RIIb siRNAs are not limited to specific sequences, and any siRNA sequence capable of inhibiting the binding between A ⁇ and Fc ⁇ RIIb by suppressing the expression of Fc ⁇ RIIb may be used.
- an Fc ⁇ RIIb-specific siRNA consists of sense and antisense sequences, which are represented by SEQ ID Nos . 11 and 12. Sense and antisense sequences are suitably annealed and inserted into a pSuper- neo vector (Oligoengine, USA) .
- a siRNA expression vector useful in the present invention is not specifically limited, but is preferably prepared by introducing a nucleotide sequence corresponding to the siRNA into a commonly used siRNA expression vector, psiRNA (Invitrogen, USA), pRNA (GenScript, USA), psLentGene (USA), pSIREN (Clontech, USA), pU ⁇ shX (VectorCoreA, Korea), pSilencer (Ambion, USA) , or pSuper-neo (Loigoengine, USA) .
- siRNA expression vector useful in the present invention is not specifically limited, but is preferably prepared by introducing a nucleotide sequence corresponding to the siRNA into a commonly used siRNA expression vector, psiRNA (Invitrogen, USA), pRNA (GenScript, USA), psLentGene (USA), pSIREN (Clontech, USA), pU ⁇ shX (VectorCoreA, Korea),
- the vector may be introduced into the nucleus of cells in the form of pure plasmid DNA or a complex with a transfection reagent or a target delivery substance, or in the form of a recombinant virus vector.
- Suitable viral vectors for use in the present invention include adenovirus, adeno- associated virus, and retrovirus including lentivirus.
- Antisense nucleotides have been approved as drugs having potential for therapeutic application to various human diseases. According to the Watson-Crick base pairing rules, a nucleotide is annealed to (hybridized with) a complementary sequence of DNA, immature mRNA or mRNA to interrupt the transmission of genetic information. The specificity of antisense nucleotides to target sequences makes them exceptionally multi-functional. An antisense- nucleotide is a long chain of monomer units and thus can be readily synthesized to correspond to a target RNA sequence. Many reports have recently demonstrated the usefulness of antisense nucleotides as a biochemical tool in the study of target proteins (Rothenberg et al . , J. Natl.
- an antisense oligonucleotide targeting cmyb has been used to completely eliminate myelogenous leukemia cells from the bone marrow of patients suffering from myelogenous leukemia (Gewirtz and Calabreta, U.S. Pat. No. 5,098,890).
- Antisense nucleotides are known to have in vivo therapeutic efficacy on cytomegalovirus retinitis.
- Antisense nucleotides to Fc ⁇ RIIb are not limited to specific sequences, but any antisense nucleotides inhibiting the binding between A ⁇ and Fc ⁇ RIIb by suppressing the expression of Fc ⁇ RIIb may be used.
- the present invention provides a pharmaceutical composition for preventing or treating AD comprising the interaction inhibitor as an effective ingredient.
- the present composition includes the effective ingredient in an amount of 0.0001 to 50 wt% based on the total weight of the composition.
- the present composition may include one or more effective ingredients exhibiting functions that are the same as or similar to the interaction inhibitor.
- the present composition may also include, in addition to the aforementioned effective ingredients, one or more pharmaceutically acceptable carriers for administration.
- the pharmaceutically acceptable carrier may include saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes and mixtures of two or more thereof.
- the composition may further include other typical additives, such as antioxidants, buffers, and bacteriostatics.
- diluents, dispersing agents, surfactants, binders and lubricants may be further added so as to be formulated into injectable formulations, such as solutions, suspensions and emulsions, pills, capsules, granules or tablets.
- the carrier may be conjugated to a target site-specific antibody or other ligands so as to act specifically in the target site.
- the composition may be desirably formulated according to each disease or ingredient using a proper method in the art or the method described in Remington's Pharmaceutical Science (updated version, Mack Publishing Company, Easton PA) .
- the pharmaceutical composition of the present invention is administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or locally) .
- the dosage may vary depending on the patient's weight, age, gender, health state and diet, administration time, administration mode, excretion rate, and severity of illness.
- the daily dosage ranges from about 0.01 to 500 mg/kg, and preferably from 0.1 to 50 mg/kg.
- the daily dosage may be taken as a single dose or divided into several doses.
- the present invention provides a method of screening a substance inhibiting the binding between A ⁇ and Fc ⁇ RIIb, Fc ⁇ RIIb-mediated signal transduction, or the intracellular translocation of A ⁇ and F ⁇ RIIb. i) The present invention provides a method of screening an inhibitor of the interaction between A ⁇ and Fc ⁇ RIIb.
- the screening method includes the steps of 1) adding a compound to be tested before, after or during the binding between all or part of Fc ⁇ RIIb and all or part of A ⁇ ; 2) measuring the binding degree between Fc ⁇ RIIb and A ⁇ ; and 3) determining whether the compound reduces the binding between A ⁇ and Fc ⁇ RIIb in comparison with a control.
- the entire Fc ⁇ RIIb protein may have the sequence of SEQ ID No. 36, and the partial portion of Fc ⁇ RIIb may be an Fc ⁇ RIIb extracellular region which is represented by SEQ ID No. 38.
- the entire A ⁇ protein may have the sequence of SEQ ID No. 34, and the partial portion of A ⁇ may be an N- terminal region of A ⁇ .
- the screening may be carried out using various methods analyzing protein-protein interaction, which are known to those skilled in the art.
- Such methods for analyzing the association between proteins include yeast two-hybrid system (Parida et al., Tuberculosis, 85: 347-355, 2005), immunoprecipitation (IP), BIAcoreTM, Fluorescence Energy Transfer (FRET), and GST-full down assay (Lee S. Y., Biochem. Biophys. Res. Commun., 334: 1445-1451, 2005), but the present invention is not limited thereto, and any known methods for analyzing the association between proteins may be used.
- the present invention provides a method of screening an inhibitor of Fc ⁇ RIIb.
- the screening method includes the steps of 1) contacting all or part of Fc ⁇ RIIb with a compound to be tested; 2) measuring the binding degree of the compound to Fc ⁇ RIIb; and 3) determining whether the compound has high binding affinity to Fc ⁇ RIIb in comparison with a control.
- the entire Fc ⁇ RIIb protein may have the sequence of SEQ ID No. 36, and the partial portion of Fc ⁇ RIIb may be an Fc ⁇ RIIb extracellular region, which is represented by SEQ ID No. 38.
- the screening may be carried out using various methods analyzing protein-compound interaction, which are known to those skilled in the art. Such methods include MALDI-TOF, but the present invention is not limited thereto, and any known methods for analyzing the association between a protein and a compound may be used.
- the present invention provides a method of screening a substance inhibiting the expression of Fc ⁇ RIIb.
- the screening method includes the steps of 1) treating a brain cell culture with a compound to be tested; 2) measuring the expression level of Fc ⁇ RIIb in the brain cell culture; and 3) determining whether the compound inhibits Fc ⁇ RIIb expression in comparison with a control.
- B103 cells or primary neuronal cells from the cerebral cortex may be used, but the present invention is not limited thereto, and any known cell lines expressing Fc ⁇ RIIb may be used.
- the Fc ⁇ RIIb expression may be assessed using RT-PCR, an immunoassay, and the like, but the present invention is not limited thereto, and any known methods for measuring the amount of a transcript or a protein translated therefrom may be used.
- the present invention provides a method of screening a substance inhibiting the intracellular translocation of A ⁇ and Fc ⁇ RIIb.
- the screening method includes the steps of 1) treating a brain cell culture with A ⁇ and a compound to be tested; 2) detecting the intracellular level of A ⁇ in the brain cell culture; and 3) determining whether the compound inhibits the intracellular translocation of A ⁇ in comparison with a control.
- B103 cells or primary neuronal cells from the cerebral cortex may be used, but the present invention is not limited thereto and any known cell lines expressing Fc ⁇ RIIb may be used.
- the intracellular translocation of A ⁇ may be assessed using antibodies, compounds and peptides binding specifically to A ⁇ or FcyRIIb.
- a ⁇ and FcyRIIb may be detected using a protein conjugated to a fluorescent, colorimetric or radioactive protein, compound or peptide.
- a ⁇ and Fc ⁇ RIIb may be detected using fluorescence detection, radioactive detection and colorimetric detection apparatuses .
- the present invention provides a method of screening a substance inhibiting the interaction between A ⁇ and Fc ⁇ RIIb using an Fc ⁇ RIIb chimeric protein.
- the screening method includes the steps of 1) treating a cell line expressing an Fc ⁇ RIIb chimeric protein with A ⁇ and a compound to be tested; 2) measuring the activity of the Fc ⁇ RIIb chimeric protein; and 3) determining whether the compound inhibits the activity of the chimeric protein in comparison with a control.
- the Fc ⁇ RIIb chimeric protein is a receptor, and any protein capable of measuring the force of interaction between A ⁇ and Fc ⁇ RIIb, as determined through the expression, color development or color change thereof, or the cellular signal transduction mediated thereby, may be fused to Fc ⁇ RIIb.
- the Fc ⁇ RIIb chimeric protein may be created by linking Fc ⁇ RIIb to a specific protein, of which the expression, color development, color change or cellular signal transduction is stimulated upon the interaction between Fc ⁇ RIIb and A ⁇ .
- CD-40 which activates cellular signal transduction, was linked to Fc ⁇ RIIb.
- the transmembrane protein CD-40 mediating intracellular signal transduction was used, but a protein such as tyrosine receptor kinase (TRK) , which contains both a transmembrane domain and a cytoplasmic domain, is preferred.
- TRK tyrosine receptor kinase
- the present invention is not limited thereto .
- the present invention provides a method of screening a substance inhibiting the interaction between A ⁇ and F ⁇ RIIb using a software program.
- the screening method includes the steps of 1) inputting information about the structure of a compound to be tested into a software program; and 2) determining whether the compound inhibits the binding between A ⁇ and Fc ⁇ RIIb using the software program.
- the software program useful in the method may be selected from the group consisting of DOCKTM, FlexXTM, and AffinityTM.
- the present inventors employed an Affinity Program (InsightII, Accelrys Inc) .
- a compound inhibiting A ⁇ -Fc ⁇ RIIb interaction may be determined based on 1) the protein structure of Fc ⁇ RIIb, containing amino acids corresponding to glutamic acid at position 64, tryptophan at 132, tryptophan at 155, lysine at 156 and lysine at 158 of SEQ ID No. 36, and 2) the protein structure of A ⁇ , containing amino acids corresponding to glutamic acid at position 3, phenylalanine at 4, histidine at 6 and aspartic acid at 7 of SEQ ID No. 34.
- the present invention provides a method for screening of an inhibitor of intracellular kinase acting downstream of Fc ⁇ RIIb.
- the present inventors confirmed that apoptosis occurred via activations of various intracellular kinases when oligomeric A ⁇ bound to Fc ⁇ RIIb through a series of experiments using expression inhibitors and activity inhibitor of the kinases.
- the preferred intracellular kinase is Syk, Btk, Lyn, IP3K, JNK, GSK or IMPase, but not limited thereto.
- the screening of an inhibitor inhibiting activity of the intracellular kinases may be performed by methods well- known in the art. Particularly, in a preferred embodiment the method is selected from a group consisting of: i) Reacting an intracellular kinase, a substrate specific for the kinase and test compounds, and selecting a test compound reducing the extent of phosphorylation of said kinase comparing to control which is not treated with the test compound; ii) Reacting an intracellular kinase and test compounds, and selecting a test compound which is binding to the kinase; and iii) Reacting an intracellular kinase, a substrate specific for the kinase and test compounds, and selecting a test compound inhibiting the interaction between the kinase and the substrate comparing to control which is not treated with the test compound.
- the extent of phosphorylation of the kinase may be determined by various methods, for example, isotopes such as 32 P or 33 P, an agarose electrophoresis analysis in which the charge of a phosphorylated substrate changes by -2 or detection using antibodies specific for phosphorylated kinases may be used.
- the present invention provides a method of diagnosing Alzheimer' s disease by measuring the expression level of Fc ⁇ RIIb.
- the expression level of Fc ⁇ RIIb may be detected using any known methods capable of measuring the expression level of the Fc ⁇ RIIb protein. Examples of such methods include, but are not limited to, an immunoassay with an antibody binding specifically to Fc ⁇ RIIb, and RT-PCR and Northern blotting with nucleic acid molecules capable of complementarily binding to the FcyRIIb gene.
- the present invention provides a kit for diagnosing Alzheimer' s disease by measuring the expression level of Fc ⁇ RIIb.
- the diagnostic kit may include DNA, RNA and a protein, binding specifically to Fc ⁇ RIIb, a buffer, a standard antibody, a secondary antibody labeled with an enzyme catalyzing a colorimetric reaction or a fluorescent substance, and a substance for color development. Also, when a compound binding specifically to Fc ⁇ RIIb is used, this compound is used in a form in which it is conjugated to a fluorescent or colorimetric label, which may be visually detected.
- the present invention also provides a method of diagnosing Alzheimer's disease using the diagnostic kit. The method includes the steps of 1) collecting a specimen from a subject; 2) reacting the specimen with a substance binding specifically to Fc ⁇ RIIb and washing the specimen; and 3) measuring the amount of the specifically bound substance.
- step 3 when an antibody specific to Fc ⁇ RIIb is used, the antibody is allowed to react with a secondary antibody conjugated to a fluorescent substance, is washed, and is analyzed using a fluorescence microscope or scanner.
- the bound compound may be quantified in a bound or separated state.
- the present invention provides a therapeutic agent for treating AD comprising an activity inhibitor or an expression inhibitor of intracellular kinase acting downstream of Fc ⁇ RIIb.
- the intracellular kinase is preferably Syk, Btk, Lyn, IP3K, JNK, GSK or IMPase, but not limited thereto.
- the activity inhibitor may be one known to the art, and a compound screened in the above method of vii, IV may be used.
- LY294002 As the activity inhibitor, LY294002, SP600125, LiCl, L-690,330 or piceatannol, etc. may be used, but not limited thereto.
- antisense oligonucleotides, siRNA, miRNA or shRNA specific for the intracellular kinases may be used, but not limited thereto.
- the therapeutic agent of the present invention is administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or locally) .
- the dosage may vary depending on the patient's weight, age, gender, health state and diet, administration time, administration mode, excretion rate, and severity of illness.
- the daily dosage ranges from about 0.01 to 500 mg/kg, and preferably from 0.1 to 50 mg/kg.
- the daily dosage may be taken as a single dose or divided into several doses.
- FIG. 1 shows the Fc ⁇ RIIb expression, increased upon exposure to A ⁇ i- 42 , which was detected using RT-PCR (a) , Western blotting (b) and immunostaining (c) : A ⁇ : A ⁇ i_ 42 ; Bapta: Bapta-AM; CaIp.: Calpeptin; Asc. : Ascorbic acid; and
- Tuni tunicamycin.
- FIG. 2 shows neuronal cell death induced by overexpression of Fc ⁇ RIIb and an Fc ⁇ RIIb mutant.
- FIG. 3a is a photograph showing results of western blot analyzing effect of siRNA against Fc ⁇ RIIb and a siRNA against RAGE
- FIG. 3b is a graph comparing degree of cell death of various cell lines: pSuper-Neo: mock vector; siFc ⁇ RIIb #1: siRNA-expressing cell line #1; siFc ⁇ RIIb #2: siRNA-expressing cell line #2; siRAGE #1: siRNA-expressing cell line #1; and siRAGE #2: siRNA-expressing cell line #2) .
- FIG. 4a is a photograph showing western blotting analyzing effect of treatment of Fc ⁇ RIIb extracellular domain (ED), and FIG. 4b is a graph comparing a relative ratio of cell death treated with A ⁇ and/or Fc ⁇ RIIb ED:
- FIG. 5a and 5b are photographs showing the results of immunohistochemical analysis for Fc ⁇ RIIb expression levels in the brains of Tg2576 mice, and AD patients, respectively.
- FIG. 6 is a photograph showing the results of immunostaining for intracellular accumulation of A ⁇ i-42 in siFc ⁇ RIIb-transfected cells.
- FIG. 7a is a photograph showing the results of an in vitro binding assay between Fc ⁇ RIIb and A ⁇ i_ 4 2 using gel shift assay
- FIG. 7b is a graph showing whether Fc ⁇ RIIb binds to A ⁇ i_ 4 o and A ⁇ i- 42 using surface plasraon resonance analysis :
- FIG. 8a is a schematic diagram an Fc ⁇ RIIb-CD40 chimeric protein
- FIG. 8b is a graph shwong the stimulation of NF- ⁇ B activation when A ⁇ i_ 42 binds to Fc ⁇ RIIb.
- FIG. 9 is a computer simulation showing the predicted binding site structure of A ⁇ i_ 42 and Fc ⁇ RIIb.
- FIG. 10a depicts the sequences of peptides antagonizing the binding between A ⁇ i- 42 and Fc ⁇ RIIb and FIG. 10b is a graph showing degree of inhibition among the antagonistic peptides.
- FIG. 11a and lib are graphs showing the effects of the peptides inhibiting the binding between A ⁇ i_ 42 , Fc ⁇ RIIb on A ⁇ -induced neurotoxicity in hippocampal neurons and cortical neurons, respectively.
- FIG. 12 is a series of graphs showing the inhibitory effects of the peptides inhibiting the binding between A ⁇ i_ 42 and Fc ⁇ RIIb on memory decline: a and b: Y-maze test; and c and d: passive avoidance test.
- FIG. 13 is a series of photographs showing the results of immunostaining for intraneuronal accumulation of A ⁇ i- 42 in neurons treated with peptides inhibiting the binding between A ⁇ i_ 42 and Fc ⁇ RIIb.
- FIG. 14a is a graph showing the results of experiments for investigating whether siRNAs against various intracellular kinases can inhibit apoptosis of neuronal cells, which is induced by overexpression of Fc ⁇ RIIb, and
- FIG. 14b is a graph showing the result of experiments for investigating whether the siRNAs can inhibit apoptosis of neuronal cells, which is induced by interaction between A ⁇ _
- FIG. 15a is a graph showing the results of experiments for investigating whether inhibitors of various intracellular kinase can inhibit apoptosis of neuronal cells, which is induced by overexpression of Fc ⁇ RIIb
- FIG. 15b is a graph showing the result of experiments for investigating whether the inhibitors can inhibit apoptosis of neuronal cells, which is induced by interaction between A ⁇ i- 42 and Fc ⁇ RIIb.
- EXAMPLE 1 Gene expression profiling using DNA microarray
- Neuronal cells were isolated from the cerebral cortex of 16 day-old rat embryos and cultured. The primary- cultured cortical neuronal cells were exposed to 5 ⁇ M of A ⁇ (500 ⁇ M in PBS; Sigma, USA) for 24 hrs . Total RNA was isolated from the cells using TRIZOL Reagent (GIBCO-BRL, USA) according to the manufacture's protocol. Gene expression was analyzed using DNA microarray filters (GF300, GF301, GF302, Invitrogen, USA) containing 17,000 rat cDNAs according to the manufacturer's instruction. Results obtained from three independent experiments were statistically analyzed using the Pathway3TM software program (ResgenTM, Invitrogen, USA) .
- RNA for reverse transcription was isolated using TRIZOLR Reagent (Invitrogen, USA) .
- cDNAs were synthesized through reverse transcription, which was carried out using 5 ⁇ g of total RNA and ImProm-IITM Reverse Transcriptase (Promega, USA) according to the manufacturer's protocol.
- RT-PCR was performed using the following primers: Fc ⁇ RIIb-5 ' -EcoRI primer (5'- CGCGGAATTCGATGGACAGCAACAGGACT-3' : SEQ ID No.
- Fc ⁇ RIIb-3'- Kpnl primer (5'-CGGGTACCATAATGTGGTTCTGGTAGTC-S' : SEQ ID NO. 2), Fc ⁇ RI-RT-5' primer (5'-TTGGTGAACACAGTTCTCTATGTGAAAATAC- ACAGGCTGC-3' : SEQ ID No. 3), Fc ⁇ RI-RT-3' primer (5'- CTATCTTACAGTGGCTGTTACTTCTTCATACACGTCATCGCT-S': SEQ ID NO. A), Fc ⁇ RIIa-RT-5' primer (5'-GCCGATTTCTGCCTAGTGATGTGCCTCCTGTTTGCA- GTGG-3': SEQ ID No.
- ⁇ -actin was used as an internal control, and was amplified with the ⁇ -actin sense primer (5'-GCGTCCACCCGCGAG-S' : SEQ ID NO. 7) and the ⁇ -actin anti-sense primer (5'-TATAGCAGGGTCAAC-S' : SEQ ID No. 8) .
- PCR was carried out in a total volume of 50 ⁇ 1 using one-fifth of the reverse transcription reaction solution as a template.
- PCR conditions included denaturation at 95 ° C for 5 min, and 10, 15, 20 or 25 cycles of denaturation at 95 ° C for 60 sec, annealing at 56 ° C for 60 sec and extension at 72 ° C for 60 sec, followed by final extension at 72 ° C for 7 min.
- EXAMPLE 2-2 Western blot analysis
- Rat B103 neuronal cells were treated with a calcium chelator (BAPTA-AM, 5 ⁇ M; EGTA, 1 mM) , a calpain protease inhibitor (calpeptin, 10 ⁇ M) , and an antioxidant (ascorbic acid, 5 ⁇ M) for 2 hrs, and exposed to A ⁇ for 48 hrs. Then, cells were lysed with a sampling buffer (10% glycerol, 2% SDS, 62.5 mM Tris-HCl, 2% ⁇ -mercaptoethanol, pH 6.8).
- BAPTA-AM calcium chelator
- calpeptin 10 ⁇ M
- an antioxidant ascorbic acid, 5 ⁇ M
- the cell lysates were separated on a 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, and transferred onto a nitrocellulose membrane.
- Western blotting was performed with the primary antibody, monoclonal K9.631 (a gift from Dr. Hammerling, Memorial Sloa Kettering Cancer Center, NY) and goat anti-mouse IgG antibody-conjugated horseradish peroxidase as a secondary antibody (Santa Cruz Biotechnology, USA) .
- a control was incubated with anti- ⁇ -tubulin antibody (T5168) (Sigma, USA) and the same HRP-conjugated secondary antibody.
- the Western blotting showed that the A ⁇ -induced Fc ⁇ RIIb expression was not suppressed upon treatment with the calcium chelators, calpain protease inhibitor and antioxidant (FIG. Ib) .
- the A ⁇ -induced Fc ⁇ RIIb expression seems to occur in a specific manner.
- the Fc ⁇ RIIb expression increased even upon the blocking of the action of calcium and active oxygen species, which mediate the toxic signaling of A ⁇ , indicating that A ⁇ acts upstream of A ⁇ signaling to induce Fc ⁇ RIIb expression.
- Example 2-1 B103 cells were exposed to PBS, tunicamycin (Tuni), which inhibits N-glycosylation as post-translational modification of proteins, and A ⁇ for 48 hrs. Cells were fixed, probed with the primary antibody monoclonal K9.631 (Memorial Sloa Kettering Cancer Center, NY) , and observed under a fluorescence microscope (Leica DMRBE, Germany) . This test was carried out as described in Song et al., Molecular cell, 12(3), 553-563, 2003. When B103 cells were exposed to A ⁇ , the expression of Fc ⁇ RIIb increased (FIG. Ic) . These results were consistent with those of the DNA microarray analysis in Example 1.
- An FcyRIIb expression vector and an Fc ⁇ RIIb mutant expression vector were constructed and transfected into rat neuronal B103 cells.
- the expression vectors were prepared as follows.
- the rat FcyRIIb gene was amplified by performing PCR using a rat brain cDNA library (Invitrogen,
- Fc ⁇ RIIb-3'-.FfpnI primer (5 ' -CGGGTACCATAATGTGGTTCTGGTAGTC-S ' : SEQ ID No. 2) .
- PCR was carried out in a total volume of 100 ⁇ 1 using 20 pmol of each primer. PCR conditions included denaturation at 95 ° C for 5 min, and 30 cycles of denaturation at 95 ° C for 60 sec, annealing at 56 ° C for 60 sec and extension at 72 ° C for 60 sec, followed by final extension at 72 ° C for 7 min.
- the amplified rat Fc ⁇ RIIb gene was inserted into pEGFP-Nl (Clonetech, USA) , and the resulting vector was designated "pFc ⁇ RIIb".
- Fc ⁇ RIIb (I232T) mutant was prepared through PCR using Fc ⁇ RIIb [I232T]-5' primer ( ⁇ '-GCTGTCGCTGGAACTGTAGCTGCC-S': SEQ ID No. 9) and Fc ⁇ RIIb [I232TJ-3' primer (5'-GGCAGCTACA- GCAGTTCCAGCGACAGC-3' : SEQ ID No. 10) .
- PCR was carried out in a total volume of 50 ⁇ 1 using 10 pmol of each primer. PCR conditions included denaturation at 95 ° C for 5 min, and 30 cycles of denaturation at 95 ° C for 5 min, annealing at 5 ⁇ ° C for 60 sec and extension at 72 ° C for 10 sec, followed by final extension at 72 ° C for 30 min.
- the amplified rat Fc ⁇ RIIb [I232T] mutant gene was inserted into pEGFP-Nl (Clonetech, USA) , and the resulting vector was designated "pFc ⁇ RIIb [I232T] ".
- This vector was digested with Dpnl , and the excised mutant gene was subjected to DNA sequencing, which was performed by the COSMO Company (Korea) . Then, B103 cells were transfected with 300 ng of pEGFP, 900 ng of pcDNA3 (void vector) , 900 ng of pFc ⁇ RIIb, and 900 ng of pFc ⁇ RIIb [I232T] using lipofectamine (Invitrogen, USA) according to the manufacturer's instructions. Cells were then exposed to 5 ⁇ M of A ⁇ and phosphate buffered saline (PBS) for 48 hrs. Cell viability was estimated under a fluorescence microscope based on the morphology of green fluorescent protein (GFP) -positive cells (expressing GFP through pEGFP introduction) .
- GFP green fluorescent protein
- Fc ⁇ RIIb-overexpressing B103 cells exhibited increased cell death, whereas neuronal cell death was inhibited in B103 cells transfected with the Fc ⁇ RIIb mutant expression vector (FIG. 2) .
- Fc ⁇ RIIb mutant expression vector FIG. 2
- siRNAs Small interfering RNAs (siRNAs) inhibiting the expression of Fc ⁇ llb and receptors for advanced glycation end-product (RAGE) , which is known as a cell surface receptor of A ⁇ , were constructed, and their effects on cell death were compared to each other.
- a siRNA duplex was formed by hybridizing sense and antisense complementary RNA oligonucleotides, listed in the following Table 1, and was inserted into pSuper-neo (Oligoengine, USA) .
- the siRNA expression vectors thus constructed were individually transfected into B103 cells using lipofectamine (Invitrogen, USA) according to the manufacturer's protocol.
- transfected cells were designated "pSuper- neo”, “psiFc ⁇ RIIb#l”, “psiFc ⁇ RIIb#2”, ⁇ psiRAGE#l", and "psiRAGE#2". Then, transfected cells were subjected to Western blot analysis.
- Western blotting was performed as described in Example 2-2 with anti-Fc ⁇ RIIb antibody (primary antibody: K9.361; secondary antibody: goat anti- mouse IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA) ) , anti-RAGE antibody (primary antibody: Sc8230 (Santa Cruz Biotechnology, USA) ; secondary antibody: donkey anti-goat IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA)), and anti- ⁇ -tubulin antibody (primary antibody: T5168 (Sigma, USA) ; secondary antibody: goat anti-mouse IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA) ) .
- anti-Fc ⁇ RIIb antibody primary antibody: K9.361
- secondary antibody goat anti- mouse IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA)
- anti-RAGE antibody primary antibody: Sc8230 (Sant
- siRNAs were found to completely suppress the expression of Fc ⁇ RIIb and RAGE (FIG. 3a) .
- the transformed B103 cells were exposed to 5 ⁇ M of A ⁇ or PBS for 48 hrs, and their viability was evaluated. Cell survival was assessed through trypan blue exclusion, Hoechst staining (Sigma, USA) , and Annexin V labeling (Promega, USA) . The survival of effector cells and cells introduced with pEGFP
- EXAMPLE 5 The effect of Fc ⁇ RIIb extracellular domain (ED) on neuronal cell death
- Fc ⁇ RIIb extracellular domain was purified as described in Sondermann et al . , EMBO J., 18:1095-1103, 1999.
- Neuronal B103 cells or primary-cultured neuronal cells were exposed to 5 ⁇ M of A ⁇ for 48 hrs . Then, cells were treated or not treated with 100 ⁇ g of the purified Fc ⁇ RIIb ED, or treated or not treated with 100 ⁇ g of bovine serum albumin (BSA) .
- BSA bovine serum albumin
- B103 cells were subjected to Western blotting, which was performed with anti-Fc ⁇ RIIb antibody as described in Example 2-2.
- the primary neuronal culture was evaluated for cell survival as described in Example 3.
- the Fc ⁇ RIIb ED Compared to BSA treatment, the Fc ⁇ RIIb ED was found to completely inhibit A ⁇ signaling in A ⁇ -exposed cells (FIG. 4), indicating that the Fc ⁇ RIIb ED is an extracellular receptor of A ⁇ . Thus, the Fc ⁇ RIIb ED may have potential as a target for inhibiting the neurotoxic signaling initiated by A ⁇ .
- EXAMPLE 6 Immunohistochemical assay The transgenic mouse used in this test was Tg2576 (18 to 24 months old, female) , which contained the human APP695 with the double mutation Lys670 ⁇ Asn and Met671 ⁇ Leu (K670N, M671L) , which was found in a large Swedish family suffering from the early onset of Alzheimer's disease (Hsiao et al . , Science, 274:99-102, 1996) .
- the mouse was anesthetized with 7% chloral hydrate, and perfused transcardially with 4% phosphate-buffered paraformaldehyde (PFA; Sigma, USA) .
- PFA phosphate-buffered paraformaldehyde
- the brain was excised and immersed in PFA for 48 hrs . Then, the brain was cut into serial coronal sections on a freezing microtome. The sections were mounted on glass slides, dried, and fixed again with 4% PFA for 15 min. The sections were incubated in methanol, containing 3% H2O2 for 5 min, to remove endogenous peroxidase activity. Then, the brain sections were washed, immersed in 0.5% Triton X-IOO for 30 min before being reacted with the primary antibody, and incubated with 1% bovine serum albumin for 1 hr.
- Specimens from fifteen patients neuropathologically diagnosed as having AD were donated from McLean Hospital (Harvard Brain Tissue Resource Center, Belmont, Massachusetts) and Ohio state university (Columbus, Ohio) . All tissues were confirmed through clinical records and neuropathological examinations .
- AD patient samples were stained with anti-A ⁇ monoclonal antibody (4G8:Signet, USA), anti-PHF-1 antibody (gift from Dr. Davis, Albert Einstein College of Medicine, NY) .
- EXAMPLE 7 Evaluation of intracellular A ⁇ accumulation in B103 cells transfected with siRNA expression vectors psiFc ⁇ RIIb #1 cells or psiRAGE #1 cells, prepared in Example 4, were exposed to 100 nM of A ⁇ or PBS for 12 hrs, and immunostained with anti-A ⁇ antibody (4G8; Signet, USA) according to the same method as in Example 2-3. Intracellular A ⁇ accumulation was strongly inhibited in psiFc ⁇ RIIb cells but was maintained in psiRAGE cells, indicating that Fc ⁇ RIIb mediates the intracellular accumulation of A ⁇ in neurons (FIG. 6) . Thus, psiFc ⁇ RIIb of Fc ⁇ RIIb mutants may be useful in inhibiting intraneuronal A ⁇ accumulation.
- EXAMPLE 8 Jn vitro assay for the binding between Fc ⁇ RII and ⁇ i_ 42
- EXAMPLE 8-1 Gel shift assay 5 ⁇ M of A ⁇ was mixed with 20 ⁇ g of Fc ⁇ RIIb-ED or 20 ⁇ g of BSA in vitro, and was incubated at 37 ° C for 3 hrs. The reaction mixture was incubated with anti-Fc ⁇ RIIb polyclonal antibody or anti-GST antibody for 2 hrs, and then with Protein G for 3 hrs (binding solution: 50 mM Tris-HCl, pH 7.4, 1 mM DTT, 0.5 mM EDTA, 0.01% Triton X-100, 0.5 mg/ml bovine serum albumin, 10% (v/v) glycerol, protease inhibitors cocktail, several concentrations of NP-40) .
- the beads were washed three times and subjected to Western blotting to assess the association between Fc ⁇ RII and A ⁇ i- 42 - Western blotting was carried out with K9.361 antibody and anti-A ⁇ antibody (primary antibody: 71-5800 (Zymed, USA) ; secondary antibody: goat anti-rabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA) .
- a ⁇ was found to directly bind to Fc ⁇ RIIb-ED (FIG. 7a) .
- the present inventors performed surface plasmon resonance assay.
- the inventors attached BSA and Fc ⁇ RIIb- ED into CM5 chip (GE Healthcare, USA) and then determined binding activity with A ⁇ i_ 42 using Biacore 3000 (GE Healthcare, USA) (FIG. 7b) .
- a ⁇ i_ 40 showed weaker affinity than A ⁇ i- 42 . This suggests that Fc ⁇ RIIb binds to A ⁇ i- 42 preferentially.
- EXAMPLE 9 Evaluation of the binding between Fc ⁇ RIIb-CD40 chimera and A ⁇
- Fc ⁇ RIIb binds to A ⁇ in a specific manner, an extracellular domain of Fc ⁇ RIIb was genetically fused to CD40, consisting of a transmembrane domain and a cytoplasmic domain.
- the resulting Fc ⁇ RIIb- CD40 fusion gene was expressed in NIH3T3 cells to increase NF-KB activity, a signal transducer of CD40, when the fusion protein binds to A ⁇ .
- the chimeric gene was constructed as follows: A rat Fc ⁇ RIIb extracellular region and human CD40 transmembrane and cytoplasmic domains were amplified by performing PCR with Fc ⁇ RIIb-ED-5 ' -Nhel primer (5 ' -GCTAGCGCTATGGACAGCAACAGGACT-S ': SEQ ID No. 15), Fc ⁇ RIIb-ED-3'-Hi ⁇ d III primer (S'-AAGCTTGGGAGGCAACGAACTGC- TGGATTT3': SEQ ID No. 16), CD40-TM+cyto-5 ' primer (5 1 - CCCAAGCTTGGGGCCCTGGTGGTGATCCCCATC-3' : SEQ ID No.
- a computational study revealed the assembly of A ⁇ monomers into a globular soluble oligomeric structure, in which N- terminal tails are exposed to the exterior and C-terminal hydrophobic regions aggregate to form an oligomer (Urbane, B. et al. Proc.Natl. Acad. Sci. U. S. A. 101:17345-17350, 2004) . Also, the N-terminal structure of oligomers was similar to that of monomeric A ⁇ .
- Fc ⁇ RIIb binds the N-terrainal region of A ⁇ , and identified first the binding site structures between Fc ⁇ RIIb and A ⁇ using the N- terminal structure of A ⁇ , which was determined through a nuclear magnetic resonance (NMR) study of a computational prediction method (Affinity ® program: InsightII, Accelrys Inc) .
- NMR nuclear magnetic resonance
- Affinity ® program: InsightII, Accelrys Inc The structures of the binding regions in Fc ⁇ RIIb and A ⁇ were determined using a known crystal structure of FcyRIIb (Sondermann, P. et al . , EMBO J. 18: 1095-1103, 1999) .
- Fc ⁇ RIIb When a tryptophan residue critical for the binding of Fc ⁇ RIIb to IgG was replaced with alanine, Fc ⁇ RIIb showed remarkably reduced binding affinity to A ⁇ .
- the structure prediction was carried out by placing the N- terminal region of A ⁇ proximate into a tryptophan pocket of Fc ⁇ RIIb.
- a ⁇ i-42 Phe4 was first artificially located closed to Trp92 and Trpll5 residues of hFc ⁇ RIIb, and the general binding procedure was then performed as follows. Molecular dynamic calculations for the binding between hFc ⁇ RIIb and A ⁇ were carried out using the CVFF force field.
- the initial structure was generated using a Monte Carlo minimization method, and simulated to generate actual non-bond contacts using a Cell Multipole method. Such simulated annealing started at 500 K, and the temperature was slowly cooled down to 300 K for stabilization through over 50 steps, followed by a final round of over 1000 steps of energy minimization for final structure calculation.
- Example 10 Based on the results of Example 10, a sequence spanning from the first to ninth residues from the N- terminus of A ⁇ , and a 95 to 101 sequence and a 107 to 114 sequence of mouse Fc ⁇ RIIb, which are A ⁇ docking sites, were synthesized. Also, peptides, in which a residue involved in A ⁇ -c ⁇ RIIb binding in the above sequences was replaced with alanine, were synthesized. The peptides (wild type and mutant) have the sequences represented by SEQ ID Nos. 24 to 33 (FIG. 10a) . The synthesized peptides were individually allowed to react with a mixture of FcyRIIb- CD40 and A ⁇ (5 ⁇ M) or PBS. Then, luciferase activity was measured.
- EXAMPLE 12 Inhibition of A ⁇ -induced neurotoxicity using the peptides inhibiting Fc ⁇ RIIb-A ⁇ binding
- rat primary neuronal cells were treated with the peptides (15 ⁇ M each) prepared in Example 11 and A ⁇ (5 ⁇ M) for 48 hrs. Relative cell survival rates were then measured and compared with a control.
- hippocampal neurons were treated with peptides #1 to #7
- rat cortical neurons were treated with peptides #8 to #10.
- binding inhibitory peptides were found to inhibit the neuronal toxicity induced by A ⁇ through its binding to
- Fc ⁇ RIIb Fc ⁇ RIIb (FIG. 11) .
- the peptides are able to strongly inhibit the neurotoxic signaling of A ⁇ , they may be useful in the prevention and treatment of AD.
- mice were not used in this test because it takes a lot of time to breed the animals, and they are expensive. Instead, normal mice were used in this memory test because the same AD symptoms as in Tg2576 mice were observed when A ⁇ was injected into the brains of normal mice.
- Normal BALB/c mice were injected intracerebro- ventricularly (i.c.v.) with A ⁇ (1.855 ⁇ g/5 ⁇ l, 410 pmole) alone or in combination with a specific peptide. After one day, a Y-maze test and a passive avoidance test were performed. Memory was assessed as described in Yan et al. ⁇ Br. J. Pharmacol. , 133:89-96, 2001) . When mice received i.c.v.
- peptides #1 and #9 may be effective in the prevention and treatment of AD.
- Brain specimens were prepared from the mice of Example 13 according to the same method as in Example 6. Sections were immunostained with primary antibodies, anti-A ⁇ antibody (Biosource, USA) plus an antibody to a marker of neurons, anti-neuron specific enolase (NSE) antibody
- anti-mouse-FITC antibody goat anti-mouse IgG conjugated to FITC (Santa Cruz Biotechnology, USA)
- anti- mouse-TRITC antibody goat anti-mouse IgG conjugated to TRITC (Santa Cruz Biotechnology, USA)
- anti-rabbit- goat-anti-mouse IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA)
- EXAMPLE 15-1 Analysis of change of apoptosis by knock-out of kinases through shRNAs
- the present inventors analyzed degree of apoptosis after knocking out various kinases which are predicted to act downstream of Fc ⁇ RIIb using shRNAs against the kinase genes in order to investigate which molecules mediate intracellular signaling when oligomeric A ⁇ s bind to Fc ⁇ RIIb.
- the inventors transfected mouse hippocampal cell line HT22 with pFc ⁇ RIIb prepared in the Example 3 and recombinant vectors prepared by inserting oligonucleotides encoding shRNA sequence specific for kinases Syk, Btk, Lyn and AbIl (SEQ ID NOs: 19 to 23, respectively, See Table 2) into pSM2c (Open Biosystems, USA) . After incubating for 24 hours, we observed inhibitory effects of shRNA of those kinases on apoptosis induced by Fc ⁇ RIIb.
- EXAMPLE 15-2 Analysis of apoptosis change by kinase inhibitors
- the present inventors measured degree of apoptosis using selective inhibitors of various intracellular kinases in order to confirm whether the activities of the kinases resulted from binding between oligomeric A ⁇ and Fc ⁇ RIIb.
- the inventors treated a mouse hippocampal cell line, HT22, with LY294002 (Sigma, USA) which is an inhibitor of PI3K, SP600125 (Sigma, USA) which is an inhibitor of JNK, LiCl (Sigma, USA) which is an inhibitor of SK3b/IMPase, L-690,330 Tocris, USA) which is an inhibitor of IMPase, PD98059 (Sigma, USA) which is an inhibitor of MEK, and SB203580 (Sigma, USA) which is an inhibitor of p38, respectively, in a dose of 5 ⁇ M (5 mM only for LiCl) .
- the inventors treated the HT22 cells with the above kinase inhibitors and a Syk inhibitor, piceatannol (Sigma, USA) and 2 hours after the treatment the inventors treated the cells with 5 uM of A ⁇ i-42, in order to confirm whether said kinase inhibitors inhibit apoptosis due to oligomeric A ⁇ .
- the apoptosis of experimental groups pretreated with LY294002, SP600125, LiCl and L- 690,330 and piceatnannol, respectively decreased, whereas no effect was seen in the experimental group pre-treated with PD98059 and SB203580, respectively (FIG. 15b) .
- an interaction inhibitor is provided for effectively inhibiting the binding of A ⁇ to Fc ⁇ RIIb in neuronal cells and an animal model of Alzheimer's disease, thereby reducing A ⁇ -induced neurotoxicity and cell death therein.
- the present inhibitor is useful in the diagnosis, prevention and treatment of Alzheimer's disease.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070114468A KR101397554B1 (ko) | 2007-11-09 | 2007-11-09 | 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법 |
PCT/KR2008/006570 WO2009061147A1 (fr) | 2007-11-09 | 2008-11-07 | Compositions et procédé permettant de diagnostiquer, de prévenir et de traiter la maladie d'alzheimer |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2268296A1 true EP2268296A1 (fr) | 2011-01-05 |
EP2268296A4 EP2268296A4 (fr) | 2012-04-25 |
EP2268296B1 EP2268296B1 (fr) | 2015-08-12 |
Family
ID=40623919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08848333.4A Active EP2268296B1 (fr) | 2007-11-09 | 2008-11-07 | Compositions et procede permettant de diagnostiquer, de prevenir et de traiter la maladie d'alzheimer |
Country Status (4)
Country | Link |
---|---|
US (2) | US8124358B2 (fr) |
EP (1) | EP2268296B1 (fr) |
KR (1) | KR101397554B1 (fr) |
WO (1) | WO2009061147A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12030945B2 (en) | 2022-10-25 | 2024-07-09 | Seismic Therapeutic, Inc. | Variant IgG Fc polypeptides and uses thereof |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110119513A (ko) | 2010-04-26 | 2011-11-02 | 한국전자통신연구원 | 포토트랜지스터를 이용한 알츠하이머 질병의 조기 진단 방법 |
US9023607B2 (en) | 2010-04-26 | 2015-05-05 | Intellectual Discovery Co., Ltd. | Method for early diagnosis of alzheimer'S disease using phototransistor |
KR101352670B1 (ko) * | 2010-06-15 | 2014-01-17 | 울산대학교 산학협력단 | 알츠하이머 전구단백질 분비 펩타이드의 축적물을 포함하는 뇌 노화 감별 진단 마커 |
US9541561B2 (en) | 2012-06-14 | 2017-01-10 | Electronics And Telecommunications Research Institute | Method for diagnosing Alzheimer's disease using biomaterial |
KR101987272B1 (ko) * | 2017-09-15 | 2019-06-10 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2A28.1 |
KR101987268B1 (ko) * | 2017-10-12 | 2019-06-10 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2A45 |
KR101987279B1 (ko) * | 2017-10-12 | 2019-06-10 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2A45.1 |
KR101987292B1 (ko) * | 2017-10-12 | 2019-06-10 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2B45.1 |
KR101986252B1 (ko) * | 2017-09-15 | 2019-06-05 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2A28 |
KR20210048135A (ko) | 2019-10-23 | 2021-05-03 | 주식회사 에이아이플랫폼 | 망막 영상 데이터 기반의 알츠하이머치매 분석 시스템 |
KR20210048136A (ko) | 2019-10-23 | 2021-05-03 | 주식회사 에이아이플랫폼 | 망막 영상 데이터 기반의 알츠하이머치매 분석 방법 |
KR102351126B1 (ko) * | 2019-12-03 | 2022-01-13 | 재단법인대구경북과학기술원 | App 및 mdga1 단백질 상호작용 억제제를 포함하는 약학적 조성물 및 이를 이용한 스크리닝 방법 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0234733A1 (fr) * | 1986-01-27 | 1987-09-02 | Scotia Pharmaceuticals Limited | Compositions pharmaceutiques |
DE4340272C1 (de) * | 1993-11-26 | 1995-05-11 | Karla Dr Lehmann | Arzneimittel zur optimierten Behandlung des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung |
WO2002102412A2 (fr) * | 2001-06-18 | 2002-12-27 | Mcgill University | Inhibition selective de la neurotoxicite d'amyloide beta intracellulaire dans des neurones humains |
WO2003076455A2 (fr) * | 2002-03-05 | 2003-09-18 | Ramot At Tel-Aviv University Ltd. | Composition immunisante et procede permettant d'induire une reponse immunitaire contre le site de clivage de $g(b)-secretase |
WO2004013172A2 (fr) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, traitement et diagnostic de maladies associees a la formation et/ou a l'agregation de la beta-amyloide |
US20040110837A1 (en) * | 2002-02-20 | 2004-06-10 | The Trustees Of The University Of Pennsylvania | Regulation of GSK-3alpha activity for the treatment or prevention of Alzheimer's disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7186521B2 (en) * | 2000-09-25 | 2007-03-06 | The Regents Of The University Of California | Determining the effect of a substance on sequestration, uptake, and accumulation of amyloid in brain cells |
WO2004016750A2 (fr) * | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | Anticorps specifiques du recepteur fc$g(g)riib et procedes d'utilisation de ces anticorps |
US20050260213A1 (en) * | 2004-04-16 | 2005-11-24 | Scott Koenig | Fcgamma-RIIB-specific antibodies and methods of use thereof |
ES2371468T3 (es) * | 2003-11-26 | 2012-01-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | SUSTANCIA QUE SE UNE AL RECEPTOR HUMANO llb MEDIANTE Fc DE IgG (Fc? Rllb). |
-
2007
- 2007-11-09 KR KR1020070114468A patent/KR101397554B1/ko active IP Right Grant
- 2007-11-29 US US11/947,612 patent/US8124358B2/en active Active
-
2008
- 2008-11-07 WO PCT/KR2008/006570 patent/WO2009061147A1/fr active Application Filing
- 2008-11-07 EP EP08848333.4A patent/EP2268296B1/fr active Active
-
2012
- 2012-01-19 US US13/353,574 patent/US9234038B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0234733A1 (fr) * | 1986-01-27 | 1987-09-02 | Scotia Pharmaceuticals Limited | Compositions pharmaceutiques |
DE4340272C1 (de) * | 1993-11-26 | 1995-05-11 | Karla Dr Lehmann | Arzneimittel zur optimierten Behandlung des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung |
WO2002102412A2 (fr) * | 2001-06-18 | 2002-12-27 | Mcgill University | Inhibition selective de la neurotoxicite d'amyloide beta intracellulaire dans des neurones humains |
US20040110837A1 (en) * | 2002-02-20 | 2004-06-10 | The Trustees Of The University Of Pennsylvania | Regulation of GSK-3alpha activity for the treatment or prevention of Alzheimer's disease |
WO2003076455A2 (fr) * | 2002-03-05 | 2003-09-18 | Ramot At Tel-Aviv University Ltd. | Composition immunisante et procede permettant d'induire une reponse immunitaire contre le site de clivage de $g(b)-secretase |
WO2004013172A2 (fr) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, traitement et diagnostic de maladies associees a la formation et/ou a l'agregation de la beta-amyloide |
Non-Patent Citations (1)
Title |
---|
See also references of WO2009061147A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12030945B2 (en) | 2022-10-25 | 2024-07-09 | Seismic Therapeutic, Inc. | Variant IgG Fc polypeptides and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US20090123459A1 (en) | 2009-05-14 |
US9234038B2 (en) | 2016-01-12 |
WO2009061147A1 (fr) | 2009-05-14 |
KR101397554B1 (ko) | 2014-05-21 |
US20120114669A1 (en) | 2012-05-10 |
EP2268296B1 (fr) | 2015-08-12 |
KR20090048192A (ko) | 2009-05-13 |
EP2268296A4 (fr) | 2012-04-25 |
US8124358B2 (en) | 2012-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2268296B1 (fr) | Compositions et procede permettant de diagnostiquer, de prevenir et de traiter la maladie d'alzheimer | |
US10774121B2 (en) | Methods and compositions for treating neurodegenerative disorders and Alzheimer's Disease and improving normal memory | |
CA2453403C (fr) | Procedes inhibant la toxicite amyloide | |
US20140178899A1 (en) | Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1 | |
JP2023093533A (ja) | 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法 | |
JP2006213621A (ja) | Adoplinタンパク質、およびその利用 | |
JP2007525491A (ja) | Gpr49の使用による、神経変性疾患の治療 | |
WO2014209947A2 (fr) | Méthodes et compositions permettant d'inhiber le trpv4 | |
CA2782459A1 (fr) | Arf6 en tant que nouvelle cible pour le traitement de la maladie d'alzheimer | |
KR101603195B1 (ko) | Atg12 유전자의 발현 또는 활성 억제제를 유효성분으로 포함하는 알츠하이머병 예방 또는 치료용 약학적 조성물 | |
JP2007523893A (ja) | Atp7aの使用による、神経変性疾患の治療 | |
WO2010092317A1 (fr) | Modulateur nnmnat2 | |
WO2015073524A1 (fr) | Nouvelles méthodes de traitement ou de prévention de la maladie d'alzheimer | |
US20110059900A1 (en) | Diagnosing and treating hormone resistant cancers | |
US20220356218A1 (en) | Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory | |
JP2008502315A (ja) | 腫瘍サプレッサータンパク質 | |
KR20040077402A (ko) | 알쯔하이머의 진단, 예방 및 치료 조성물 | |
EP1978974A1 (fr) | Méthodes pour traiter des troubles dégénératifs avec un inhibiteur de rac1b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100927 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120323 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/04 20060101ALI20120319BHEP Ipc: G01N 33/00 20060101ALI20120319BHEP Ipc: C07K 16/28 20060101ALI20120319BHEP Ipc: A61K 38/08 20060101ALI20120319BHEP Ipc: A61K 38/16 20060101AFI20120319BHEP |
|
17Q | First examination report despatched |
Effective date: 20130325 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SNU R&DB FOUNDATION |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: JUNG, YONG-KEUN Inventor name: SONG, SUNGMIN |
|
INTG | Intention to grant announced |
Effective date: 20150422 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 741517 Country of ref document: AT Kind code of ref document: T Effective date: 20150815 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008039567 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 741517 Country of ref document: AT Kind code of ref document: T Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151113 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151112 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151212 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151214 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008039567 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151107 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
26N | No opposition filed |
Effective date: 20160513 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20151112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151130 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151130 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151107 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20081107 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150812 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231024 Year of fee payment: 16 Ref country code: DE Payment date: 20231023 Year of fee payment: 16 |